Inovio Pharmaceuticals Stock Performance
| INO Stock | USD 1.72 0.01 0.58% |
The company retains a Market Volatility (i.e., Beta) of 0.7, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Inovio Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Inovio Pharmaceuticals is expected to be smaller as well. At this point, Inovio Pharmaceuticals has a negative expected return of -0.17%. Please make sure to check out Inovio Pharmaceuticals' information ratio, skewness, as well as the relationship between the Skewness and price action indicator , to decide if Inovio Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Inovio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Last Split Factor 1:12 | Last Split Date 2024-01-25 |
1 | CORRECTIONINVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO | 01/20/2026 |
2 | Acquisition by Laurent Humeau of 4771 shares of Inovio Pharmaceuticals subject to Rule 16b-3 | 02/05/2026 |
3 | ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action INO | 02/11/2026 |
4 | INOVIO to Participate in Upcoming Scientific and Investor Conferences | 02/12/2026 |
5 | ROSEN, LEADING INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action INO | 02/17/2026 |
6 | INO INVESTOR NOTICE Faruqi Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026 | 02/19/2026 |
7 | Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO | 02/20/2026 |
8 | Levi Korsinsky, LLP Cellectra Device Manufacturing Practices at Center of Inovio Pharmaceuticals Securities Litigation | 02/23/2026 |
| Begin Period Cash Flow | 14.3 M | |
| Total Cashflows From Investing Activities | 104.1 M |
Inovio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 207.00 in Inovio Pharmaceuticals on December 5, 2025 and sell it today you would lose (34.00) from holding Inovio Pharmaceuticals or give up 16.43% of portfolio value over 90 days. Inovio Pharmaceuticals is generating negative expected returns assuming volatility of 4.9679% on return distribution over 90 days investment horizon. In other words, 44% of stocks are less volatile than Inovio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Inovio Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Inovio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.72 | 90 days | 1.72 | about 63.06 |
Based on a normal probability distribution, the odds of Inovio Pharmaceuticals to move above the current price in 90 days from now is about 63.06 (This Inovio Pharmaceuticals probability density function shows the probability of Inovio Stock to fall within a particular range of prices over 90 days) .
Inovio Pharmaceuticals Price Density |
| Price |
Predictive Modules for Inovio Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inovio Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Inovio Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Inovio Pharmaceuticals is not an exception. The market had few large corrections towards the Inovio Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Inovio Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Inovio Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | 0.70 | |
σ | Overall volatility | 0.27 | |
Ir | Information ratio | -0.02 |
Inovio Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Inovio Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Inovio Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals may become a speculative penny stock | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 217.76 K. Reported Net Loss for the year was (107.25 M) with loss before taxes, overhead, and interest of (56.65 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (104.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Inovio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Levi Korsinsky, LLP Cellectra Device Manufacturing Practices at Center of Inovio Pharmaceuticals Securities Litigation |
Inovio Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Inovio Stock often depends not only on the future outlook of the current and potential Inovio Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inovio Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27.2 M | |
| Cash And Short Term Investments | 94.1 M |
Inovio Pharmaceuticals Fundamentals Growth
Inovio Stock prices reflect investors' perceptions of the future prospects and financial health of Inovio Pharmaceuticals, and Inovio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inovio Stock performance.
| Return On Equity | -3.28 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (492.03) % | ||||
| Current Valuation | 74.64 M | ||||
| Shares Outstanding | 68.7 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 3.73 X | ||||
| Price To Sales | 651.85 X | ||||
| Revenue | 217.76 K | ||||
| Gross Profit | (56.65 M) | ||||
| EBITDA | (103.95 M) | ||||
| Net Income | (107.25 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 11.87 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.14) X | ||||
| Cash Flow From Operations | (104.08 M) | ||||
| Earnings Per Share | (2.72) X | ||||
| Market Capitalization | 118.86 M | ||||
| Total Asset | 113.2 M | ||||
| Retained Earnings | (1.73 B) | ||||
| Working Capital | 62.5 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
About Inovio Pharmaceuticals Performance
By examining Inovio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Inovio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Inovio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 184.88 | 196.63 | |
| Return On Tangible Assets | (0.85) | (0.90) | |
| Return On Capital Employed | (1.66) | (1.58) | |
| Return On Assets | (1.09) | (1.14) | |
| Return On Equity | (1.80) | (1.89) |
Things to note about Inovio Pharmaceuticals performance evaluation
Checking the ongoing alerts about Inovio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inovio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals may become a speculative penny stock | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 217.76 K. Reported Net Loss for the year was (107.25 M) with loss before taxes, overhead, and interest of (56.65 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (104.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Inovio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Levi Korsinsky, LLP Cellectra Device Manufacturing Practices at Center of Inovio Pharmaceuticals Securities Litigation |
- Analyzing Inovio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inovio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Inovio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inovio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inovio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inovio Pharmaceuticals' stock. These opinions can provide insight into Inovio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Biotechnology sector continue expanding? Could Inovio diversify its offerings? Factors like these will boost the valuation of Inovio Pharmaceuticals. Market participants price Inovio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Inovio Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.72) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
Understanding Inovio Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Inovio's accounting equity. The concept of intrinsic value - what Inovio Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Inovio Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Inovio Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.